Efficacy News and Research

RSS

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

Global weight management ingredients market to reach $13.9 million by 2015

Obesity rates, which have been steadily rising in Europe and the United States, are now increasing in Asian nations as well. While healthy eating and lifestyle management are the key solutions to weight management, they remain challenging for many consumers. As a result, the weight management ingredients market offers significant prospects worldwide.

23 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

UAB receives $1.47M NHLBI grant to study red blood cell lesion

Researchers in the University of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and Surgery have received a $1.47 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study so-called red blood cell lesion, a term given to the potentially harmful changes in red blood cells that have been stored for longer times after collection.

23 Jun 2010

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

Researchers at the Oregon Health & Science University School of Dentistry have determined that ATP-driven (adenosine triphosphate-driven) bioluminescence - a way of measuring visible light generated from ATP contained in bacteria - is an innovative tool for rapidly assessing in children at the chair-side the number of oral bacteria and amount of plaque that can ultimately lead to tooth decay.

23 Jun 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

For the very first time, a medicine has been shown to protect against the development of Alzheimer's disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761 per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer's disease by nearly 50%.

23 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression.

23 Jun 2010

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix, Inc., today announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson's disease, NLX-P101. Study participants who received NLX-P101 experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to control subjects who received sham surgery.

22 Jun 2010

Diabetic individuals living in hot climate need increased 'heat awareness'

A new survey shows that diabetic individuals who live in a hot climate have important gaps in their "heat awareness," or knowledge about proper diabetes self-care in hot weather, even though diabetes raises their risk of heat illness. The results of "Diabetes in the Desert: What Do Patients Know About the Heat?" will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Omega-3 effective for treating depression in patients without anxiety disorders

The use of Omega-3 supplements is effective among patients with major depression who do not have anxiety disorders, according to a study directed by Dr. Fran-ois Lesp-rance of the Centre de recherche du Centre hospitalier at the Universit- de Montr-al (CRCHUM), head of CHUM's Department of Psychiatry and a professor at the Universit- de Montr-al. The study was published June 15 in the online Journal of Clinical Psychiatry.

22 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

Lack of tracking of medical devices' performance raises questions about safety and efficacy

"Amid the booming use of artificial joints in the United States, the breakup between Dr. Berger and Zimmer highlights what experts say is a troubling situation for patients and doctors: when disputes arise about orthopedic implant safety, there are no independent referees or sources of information because no one tracks the performance of the devices.

22 Jun 2010

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

Ipsen today announced top line results of GuidAge®, the longest (5 years) and largest (2,854 subjects) European study in the prevention of Alzheimer's Dementia (AD). This trial was conducted according to the most stringent international standards. The aim of this study was to assess the efficacy of a 5-year treatment with EGb 761® in the prevention of Alzheimer's Dementia in a population of elderly aged 70 or more, with memory complaint spontaneously expressed to their family physician and who lived at home at the inclusion in the study.

22 Jun 2010

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

22 Jun 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time.

22 Jun 2010

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Forest Laboratories, Inc. and Merz Pharmaceuticals GmbH announced today that NAMENDA XR(TM) (memantine hydrochloride) was approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dementia of the Alzheimer's type. NAMENDA XR is a 28 mg once-daily extended-release formulation of NAMENDA.

22 Jun 2010

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Gastric bypass surgery improves Type 2 diabetes by other mechanisms in addition to weight loss and does so better than a low-calorie diet despite achieving equal weight loss, a new study finds. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Efficacy News and Research

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Global weight management ingredients market to reach $13.9 million by 2015

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

UAB receives $1.47M NHLBI grant to study red blood cell lesion

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

MJFF supports Ceregene's CERE-120 Phase 2 study for PD with $2.5M award

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Diabetic individuals living in hot climate need increased 'heat awareness'

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Omega-3 effective for treating depression in patients without anxiety disorders

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

Lack of tracking of medical devices' performance raises questions about safety and efficacy

Ipsen reports top line results from European study of GuidAge for Alzheimer's Dementia

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News